Are a hematocrit of 46.6%, red blood cell count of 5.14 ×10⁶/µL, and alanine aminotransferase (ALT) of 49 U/L normal or indicative of any pathology?

Blood Work Interpretation: Borderline Elevated Hematocrit and ALT

Your patient's hematocrit of 46.6% is at the upper limit of normal for females (or within normal range for males), the RBC count of 5.14 ×10⁶/µL is normal, and the ALT of 49 U/L represents a mild elevation that warrants further evaluation to exclude underlying liver pathology.

Hematocrit and RBC Analysis

The hematocrit of 46.6% requires gender-specific interpretation:

• For adult males: This falls within the normal range. The NKF-K/DOQI guidelines define anemia work-up thresholds at Hct <37% for males 1, meaning 46.6% is physiologically normal.

• For premenopausal females: This is borderline elevated. Normal female Hct averages around 41%, and anemia work-up begins at Hct <33% 1. A Hct of 46.6% in a female warrants consideration of:

  • Polycythemia vera (though typically requires Hct >48% in women per NCCN guidelines) 2
  • Dehydration or hemoconcentration
  • Chronic hypoxia (COPD, high altitude, smoking)
  • Secondary erythrocytosis

The RBC count of 5.14 ×10⁶/µL is within normal limits for both sexes and does not suggest a primary hematologic disorder.

Clinical Action for Hematocrit: If your patient is female, repeat the Hct after ensuring adequate hydration. If persistently elevated (especially if approaching 48%), consider JAK2 mutation testing and referral to hematology to exclude polycythemia vera 2.

ALT Elevation Analysis

The ALT of 49 U/L represents a mild elevation requiring systematic evaluation:

Updated ALT Reference Ranges

Traditional laboratory "normal" ranges (typically <40 U/L) are outdated and include individuals with subclinical liver disease. Modern evidence-based thresholds are significantly lower 3:

• Males: Upper limit of normal (ULN) = 30-34 U/L 4, 3
• Females: ULN = 19-22 U/L 4, 3

Using these updated thresholds, an ALT of 49 U/L is definitively elevated regardless of sex, representing approximately 1.5-2.5 times the appropriate ULN.

Systematic Evaluation Algorithm

Following the ACR Appropriateness Criteria and British Society of Gastroenterology guidelines 5, 6:

Step 1: Assess metabolic risk factors (most common cause of mild ALT elevation):

• BMI >25 kg/m²
• Type 2 diabetes
• Waist circumference (central obesity)
• Triglycerides >200 mg/dL
• Fasting glucose >105 mg/dL
• Total cholesterol >220 mg/dL

If ≥2 metabolic risk factors present, non-alcoholic fatty liver disease (NAFLD) is the leading diagnosis 6.

Step 2: Obtain targeted serologic testing 7, 6:

• Hepatitis B surface antigen (HBsAg)
• Hepatitis C antibody (anti-HCV)
• Autoimmune markers (ANA, anti-smooth muscle antibody) if clinically indicated
• Iron studies (ferritin, transferrin saturation) to exclude hemochromatosis
• Ceruloplasmin if age <40 years (Wilson's disease)

Step 3: Medication/toxin review:

• Alcohol consumption (AUDIT score)
• Prescription medications (statins, antibiotics, anticonvulsants)
• Over-the-counter drugs, supplements, herbal products 6

Step 4: Imaging:

• Abdominal ultrasound to assess for hepatic steatosis, cirrhosis, or biliary pathology 6

Risk Stratification for NAFLD

If NAFLD is suspected, fibrosis risk stratification is mandatory using non-invasive scores 6:

• FIB-4 score = [Age × AST] / [Platelet count × √ALT]
• NAFLD Fibrosis Score (NFS) incorporating age, BMI, glucose, platelets, albumin, AST/ALT ratio

Scores indicating low risk can be monitored; intermediate or high-risk scores require hepatology referral and consideration of elastography (FibroScan) 6.

Critical Pitfalls to Avoid

1. Do not dismiss ALT of 49 U/L as "normal" based on outdated laboratory reference ranges. This represents clinically significant elevation by modern standards 3.

2. Do not assume the elevated Hct and ALT are related unless specific conditions are present. While there is a weak correlation between Hct and ALT in population studies 8, this is primarily mediated through shared metabolic risk factors (obesity, metabolic syndrome), not a direct pathophysiologic link.

3. Do not delay evaluation in the presence of metabolic syndrome criteria. Among patients with ALT ≥34 U/L (males) or ≥22 U/L (females), 72.8% and 55% respectively show hepatic steatosis 4, and 32.7% and 22.2% meet metabolic syndrome criteria.

4. Monitor for hepatocellular carcinoma (HCC) if advanced fibrosis/cirrhosis develops. Patients with cirrhosis require ultrasound screening every 6 months regardless of etiology 9.

Immediate Next Steps

1. Clarify patient's sex and repeat Hct if female with borderline elevation
2. Calculate BMI and assess for metabolic syndrome components
3. Order: HBsAg, anti-HCV, fasting lipid panel, fasting glucose, iron studies
4. Obtain abdominal ultrasound
5. Calculate FIB-4 score once AST and platelet count available
6. Detailed alcohol and medication history

If metabolic risk factors are absent and serologies are negative, refer to gastroenterology/hepatology for further evaluation 6, as persistent unexplained ALT elevation may require liver biopsy to exclude cryptogenic liver disease.